Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Preclinical research has associated Fragment 176-191 with the following activities: Potent stimulation of lipolysis in adipocyte cell cultures and animal models Inhibition of lipogenesis reduction in new fat cell formation Preferential targeting of visceral and abdominal adipose deposits No significant interference with insulin sensitivity at research-relevant concentrations Absence of receptor desensitization effects associated with full-length hGH administration Activity independent of pituitary GH secretion, enabling direct peripheral fat signaling Modified GRF 1-29 The Short-Acting GHRH Analogue Modified GRF 1-29 (Mod GRF 1-29) is a stabilized analogue of growth hormone-releasing hormone (GHRH), specifically the biologically active 1-29 fragment of native GHRH
Mokarram N, Case A, Hossainy NN, Lyon JG, MacDonald TJ, Bellamkonda R
May improve liver health GLP-1 medications may help improve liver conditions like fatty liver disease (NAFLD) and its more serious form, NASH
Certain research synthesized data form RCTs to assess the risk of DR in SGLT2i users
Biological product research and development, medical technology research and development
2007;16 Suppl 1:383-390
